海正药业董事长回应是否进军医美：定位更多还是原料供应商

Core Viewpoint - Haizheng Pharmaceutical's establishment of a subsidiary to enter the synthetic biology sector is a culmination of years of planning, not a sudden move [1] Group 1: Company Strategy - Haizheng Pharmaceutical plans to establish a joint venture with its wholly-owned subsidiary, Huizheng International Co., Ltd., to create a synthetic biology company named Zhejiang Lunsing Synthetic Biology Technology Co., Ltd., with a registered capital of 350 million yuan [1] - The company has a strong technical foundation in biotechnology, chemical synthesis, and microbial fermentation, which it considers a core advantage for entering the synthetic biology field [1] - Haizheng Pharmaceutical has already secured exclusive agency rights for high-end functional skincare products IOMA and non-crosslinked hyaluronic acid water light needles Bioregen, marking its entry into the emerging medical beauty sector [1] Group 2: Market Positioning - The company currently positions itself primarily as a raw material supplier rather than directly entering the end market for products like hyaluronic acid and collagen [2] - Haizheng Pharmaceutical aims to create a closed-loop system integrating "raw materials - formulations" to develop its own medical beauty product portfolio [2] - Previous collaborations and agency businesses were seen as initial steps to familiarize the company with industry rules and product operations, rather than a definitive market strategy [1][2]